Press Room

8 March 2007

Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug

Read more

1 March 2007

The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers

Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.

Read more

26 February 2007

TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate…

Read more

14 February 2007

The market of recombinant coagulation factors is growing with next generation products

The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of…

Read more

5 February 2007

Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes

The emerging market of GLP-1 analogs with 2006 sales of US$ 430.2 mln in the first full market year of twice-daily exenatide attracts other players in the diabetes field, but urges them to top exenatide by more convenient products

Read more

2 February 2007

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26

A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26

Read more

11 January 2007

The right balance drives the field of PPAR agonist R&D

A strongly growing market of now more than US$ 6 bln in 2006 for only tow PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations…

Read more